Researchers are developing a stem cell-based treatment that could restore function in people with chronic spinal cord injuries. Presented at ISSCR 2026, the approach uses gliogenic neural stem cells to repair — not replace — damaged nerve fibers. A clinical trial is set to begin recruiting patients in 2027.
For the millions living with chronic spinal cord injury (SCI), effective restorative treatments have long been out of reach — but a new stem cell strategy could change that. Researchers from Keio University in Japan presented preclinical data at the ISSCR 2026 Annual Meeting showing that clinical-grade gliogenic neural stem/progenitor cells (gNS/PCs) can safely promote behavioral recovery in chronic SCI models without forming tumor-like tissue.
The key insight: chronic SCI isn't just about missing nerves — it's about damaged insulation. Residual nerve fibers often survive but lose their protective myelin sheath. Rather than trying to grow entirely new nerves, the gNS/PC approach targets remyelination by generating astrocytes and oligodendrocytes — the support cells that keep existing nerve fibers functional. Think of it as repairing the wiring, not rewiring from scratch.
Key Takeaways:
Why it matters: Chronic SCI affects people years or decades after injury, a phase where current therapies offer little hope for recovery. If this approach proves effective in humans, it could open a new treatment frontier for long-term paralysis.
